NRAS

Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates

Retrieved on: 
木曜日, 11月 10, 2022
RAF, SAN, GLOBE, III, NRAS, Investment, U.S. Securities and Exchange Commission, Nasdaq, Food, Risk, Research, Knowledge, Development, BRAF, COVID-19, Regulation of tobacco by the U.S. Food and Drug Administration, SEC, Fast Track, State Administrative Expenses, IIB, Program, Clinical trial, FGFR, Patient, Growth, Security (finance), Administration, Industry, KNTE, FDA, Pharmaceutical industry

(Nasdaq: KNTE) (Kinnate), a clinical-stage precision oncology company, today announced financial results for the quarter ended September 30, 2022, and recent corporate updates.

Key Points: 
  • (Nasdaq: KNTE) (Kinnate), a clinical-stage precision oncology company, today announced financial results for the quarter ended September 30, 2022, and recent corporate updates.
  • Announced an update from the ongoing dose escalation for KIN-2787 monotherapy in the global Phase 1 clinical trial, KN-8701.
  • Net Loss: Third quarter net loss for 2022 was $30.7 million, compared to $24.7 million for the same period in 2021.
  • Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer.

Erasca Reports Third Quarter 2022 Financial Results and Business Updates

Retrieved on: 
水曜日, 11月 9, 2022
IND, Lilly, Regents of the University of California, Research, BRAF, Therapy, Form 10-K, Security (finance), Administration, Industry, MD Anderson Cancer Center, ENA, RAS, SEC, U.S. Securities and Exchange Commission, Cancer, CRC, IPO, Patient, CEO, NSCLC, San Francisco, Eli Lilly, University, MD, COVID-19, Private Securities Litigation Reform Act, Research and development, PDAC, Annual report, Depreciation, Neoplasm, R, SHP2, HNSCC, Poster, Central nervous system, EGFR, CNS, SAN, GLOBE, NRAS, KRAS, HPV, Large-cell lung carcinoma, CA, Safety, Cetuximab, Monroe Dunaway Anderson, Pharmaceutical industry, Cryptocurrency, Pfizer

SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the fiscal quarter ended September 30, 2022, and provided business updates.

Key Points: 
  • Erasca expects its current cash, cash equivalents, and marketable securities balance to fund operations into the second half of 2024.
  • Research and Development (R&D) Expenses: R&D expenses were $28.2 million for the quarter ended September 30, 2022, compared to $20.0 million for the quarter ended September 30, 2021.
  • General and Administrative (G&A) Expenses: G&A expenses were $8.8 million for the quarter ended September 30, 2022, compared to $6.9 million for the quarter ended September 30, 2021.
  • Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.

Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results

Retrieved on: 
木曜日, 11月 3, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Private Securities Litigation Reform Act, NRAS, FDA, Tenosynovial giant cell tumor, PFS, Research, U.S. Securities and Exchange Commission, Clinical trial, Oncology, European Society for Medical Oncology, SEC, Pain, Company, TGCT, Journal, LLC, Food, MEK, Congress, D, Senior, Financial toxicity, Sprint, Feedback, NF1, Binimetinib, Patient, Cancer, United Kingdom, Food and Drug Administration, Progression-free survival, ESMO, Journal of Clinical Oncology, COVID-19, ULK, RAS, RAF, RECIST, III, GIST, Safety, Medicine, NASDAQ, Union, Public expenditure, II, BRAF, Pharmaceutical industry, Fossil fuel, Video game, Twitter

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the third quarter ended September 30, 2022 and provided a corporate update.
  • Cash Position: As of September 30, 2022, cash, cash equivalents, and marketable securities were $371.6 million, compared to $393.1 million as of June 30, 2022.
  • Deciphera will host a conference call and webcast to discuss this announcement today, November 3, 2022, at 8:00 AM ET.
  • Deciphera, the Deciphera logo, QINLOCK, and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC.

Aptose Reports Results for the Third Quarter 2022

Retrieved on: 
火曜日, 11月 1, 2022
APS, TP53, Plasma, Venetoclax, Continuity, KRAS, GLOBE, Research, ASH, Bioavailability, Absorption, TSX, NRAS, NPM1, AML, Investment, NASDAQ, G1, Hand, Company, FDA, RUNX1, Patient, Acute myeloid leukemia, Exploration, USAN, PTPN11, Gene, Pharmaceutical industry, G3, FLT3, DNMT3A

SAN DIEGO and TORONTO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results for the three and nine-month periods ended September 30, 2022 and provided a corporate update.

Key Points: 
  • The net loss for the quarter ended September 30, 2022 was $9.8 million ($0.11 per share) compared with $11.3 million ($0.13 per share) for the quarter ended September 30, 2021.
  • Total cash and cash equivalents and investments as of September 30, 2022 were $55.4 million.
  • Based on current operations, Aptose expects that cash on hand and available capital provide the Company with sufficient resources to fund planned Company operations including research and development into the first quarter of 2024.
  • A summary of the results of operations for the three and nine-month periods ended September 30, 2022 and 2021 is presented below:

EQS-News: Precision Medicine Could Get Even More Precise With Allarity Therapeutics’ “Next-Generation” Diagnostics Platform

Retrieved on: 
土曜日, 10月 22, 2022
GBM, PARP, EGFR, Therapy, MYGN, Science, NRAS, Food and Drug Administration, Novartis, NYSE, NASDAQ, Neoplasm, Allar, Jerusalem, Patient, Drug development, Doxorubicin, Foundation Medicine, Research, Ixabepilone, Nasdaq, KRAS, Cancer, Food, Partnership, Company, Colorectal cancer, Safety, Advertising, Cisplatin, Association for Molecular Pathology v. Myriad Genetics, Inc., NVS, FDA, Gene, Ovarian cancer, Biomarker, Glioblastoma, Pharmaceutical industry, Medical imaging, Vaccine

Once brought into its pipeline , Allarity uses its DRP platform to develop companion diagnostics alongside each drug to improve the treatments in a personalized medicine approach.

Key Points: 
  • Once brought into its pipeline , Allarity uses its DRP platform to develop companion diagnostics alongside each drug to improve the treatments in a personalized medicine approach.
  • Allarity Therapeutics Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on oncology treatments.
  • Allaritys Drug Response Predictor (DRP) platform is a unique bioanalytical platform that can create drug-specific predictive diagnostics for a wide range of cancer treatments.
  • Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform.

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination

Retrieved on: 
木曜日, 10月 20, 2022
SAN, U.S. Securities and Exchange Commission, Pancreatic cancer, PDAC, SEC, PFE, NRAS, NYSE, Patient, ERK2, Research, Annual report, RAF, Security (finance), CRC, Investment, ERK1, RAS, GI, KRAS, Cancer, Private Securities Litigation Reform Act, Form 10-K, RTK, Mutation, ERK, NSCLC, Industry, CEO, SHP2, GLOBE, Clinical trial, Cell cycle, COVID-19, Large-cell lung carcinoma, Pharmaceutical industry, Pfizer

SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Pfizer Inc. (NYSE: PFE) for the CDK4/6 inhibitor palbociclib (IBRANCE®).

Key Points: 
  • The combination is currently being investigated as part of the ongoing Phase 1b/2 HERKULES-3 master protocol clinical trial in patients with gastrointestinal (GI) malignancies.
  • Erasca is sponsoring the study, and Pfizer is supplying palbociclib at no cost.
  • HERKULES-2 is a Phase 1b/2 master protocol clinical trial for ERAS-007 in combination with various agents in patients with non-small cell lung cancer (NSCLC).
  • HERKULES-3 is a Phase 1b/2 master protocol clinical trial for ERAS-007 in combination with various agents in patients with GI cancers.

Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute

Retrieved on: 
水曜日, 10月 19, 2022
News, U.S. Securities and Exchange Commission, Pancreatic cancer, HRAS, G4S, Colon cancer staging, Growth, Acute myeloid leukemia, AML, NRAS, Family, Neoplasm, Security (finance), Risk, RAS, Orphan drug, KRAS, Private Securities Litigation Reform Act, Form 10-K, Company, National Cancer Institute, Adult, Patent, Prostate cancer, Protein, National, Fast Track, Clinical trial, Lung cancer, Death, FDA, Cancer, Pharmaceutical industry

CARLSBAD, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the presentation of two posters detailing the Company’s RAS-Targeted platform at the National Cancer Institute-sponsored Fourth RAS Initiative Symposium to be held October 17-19, 2022 at The Advanced Technology Research Facility of the National Cancer Institute in Frederick, Maryland.

Key Points: 
  • Following screening to identify an initial candidate inhibitor against pancreatic cancer tumor growth, investigators analyzed in vitro and in vivo activity against these tumors.
  • It also suppressed xenograft development of human and mouse RAS-driven pancreatic tumor cell lines and reduced the growth of pancreatic cancer patient-derived xenograft models.
  • The study also showed that RAS-F enhanced the effects of immune checkpoint therapy in syngeneic tumor xenografts.
  • For example, mutant KRAS is found in 98% of pancreatic ductal adenocarcinomas, 52% of colon cancers, and 32% of lung adenocarcinomas.

Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial

Retrieved on: 
火曜日, 10月 11, 2022
SAN, LinkedIn, U.S. Securities and Exchange Commission, Risk, SEC, MEK, Population, Growth, Hand, FGFR, NRAS, Binimetinib, Patient, Security (finance), BRAF, RAF, Investment, II, Nasdaq, Knowledge, III, Industry, Large-cell lung carcinoma, GLOBE, Melanoma, Clinical trial, COVID-19, KNTE, Pharmaceutical industry

SAN FRANCISCO and SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) --  Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced an update from the ongoing global Phase 1 KN-8701 trial evaluating KIN-2787, an investigational pan-RAF inhibitor, in patients with BRAF-altered solid tumors and/or who have NRAS mutant melanoma.

Key Points: 
  • Enrollment in the dose escalation portion continues; currently at the 400 mg bid dose with the maximum tolerated dose not yet determined.
  • KIN-2787 achieved meaningful exposures that were dose proportional and exceeded the predicted efficacious thresholds based on preclinical models.
  • The company anticipates sharing detailed dose escalation data with additional efficacy evaluable patients in the first half of 2023.
  • Enrollment in the dose escalation portion of the trial is ongoing at sites globally, with increasing momentum.

Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium

Retrieved on: 
木曜日, 10月 6, 2022
News, U.S. Securities and Exchange Commission, Pancreatic cancer, HRAS, G4S, Colon cancer staging, Acute myeloid leukemia, AML, NRAS, Security (finance), Risk, RAS, Orphan drug, KRAS, Private Securities Litigation Reform Act, Form 10-K, Company, National Cancer Institute, Adult, Patent, Prostate cancer, Protein, National, Fast Track, Clinical trial, Lung cancer, Death, FDA, Cancer, Pharmaceutical industry

Activating mutations in one of the three human RAS gene isoforms (KRAS, HRAS, or NRAS) are present in about one-fourth of all cancers.

Key Points: 
  • Activating mutations in one of the three human RAS gene isoforms (KRAS, HRAS, or NRAS) are present in about one-fourth of all cancers.
  • For example, mutant KRAS is found in 98% of pancreatic ductal adenocarcinomas, 52% of colon cancers, and 32% of lung adenocarcinomas.
  • Our investigational QN-247 compound inhibits nucleolin, a key multi-functional regulatory protein that is overexpressed in cancer cells; QN-247 may thereby be able to inhibit the cells proliferation.
  • This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Innovate BC Awards $2.3M to B.C. R&D Projects

Retrieved on: 
金曜日, 9月 30, 2022
Hydrogen, Software, Adoption, University, Agriculture, Crown agency, Carbon, Machine learning, Technology transfer, Innovation, Okanagan College, Growth, Intellectual property, Industry, Mining, Therapy, Innovate BC, Agricultural soil science, Simon Fraser University, Natural Resources, NRAS, Technology, Quality of life, Transport, Plastic, Soil, Artificial intelligence, Germination, Method, RNA, Research, GLOBE, University of Northern British Columbia, Renewable energy, Silviculture, Oil

Vancouver, B.C., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tonight at an awards ceremony in Vancouver, Innovate BC awarded $2,325,000 to eight B.C.

Key Points: 
  • Vancouver, B.C., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tonight at an awards ceremony in Vancouver, Innovate BC awarded $2,325,000 to eight B.C.
  • Specifically, this years funding, through Innovate BCs Ignite program, is accelerating the commercialization of biotech, cleantech, mining, agriculture, and forestry projects.
  • The commercialization of these projects through Innovate BCs Ignite program will create jobs and lead to new investment opportunities for British Columbian companies.
  • Innovate BC helps foster innovation in B.C.